ctti-clinicaltrials.org

GENERAL
META
HTML
LINK ANALYSIS
SERVER
IP

Ctti-Clinicaltrials.org receives any estimated 1,123 unique visitors and 643 unique page views per day. Revenue gained from these much visits may be $0 per day from various advertising sources. The estimated worth of site is $187. Similarweb global rank is 3,634,350. Maximum no. of users comes from .

Duke University is ISP, hosted on IP 152.16.0.233 in Country United States.

Website Age n/a
Alexa Rank no-data
Country United States
IP Address 152.16.0.233

META INFORMATION

Title

Clinical Trials Transformation Initiative |

Description

CTTI is a public-private partners***p to develop and drive adoption of practices that will increase the quality and efficiency of clinical trials

Keywords

Content Type

utf-8

No	Meta Name	Value
1	viewport	width=device-width,minimum-scale=1.0,maximum-scale=1.0,initial-scale=1.0

GENERAL HTML INFORMATION

Type	Status
HTML 5
Responsive Website

HTML SIZE INFORMATION

Text / Code Ratio 13.99 %

ctti-clinicaltrials.org has a website text/code ratio of 13.99 %. Search engine crawlers tend to not pick up pages with inadequate content.

IMPORTANT HTML TAGS AND COUNTS

Titles

H10
H21
H30
H49
H515
H611

No	Text
1	Mıssıon: to develop and drive adoption of practices that will increase the quality and efficiency of clinical trials

No	Text
1	Who we are
2	What we do
3	Briefing room
4	Take action
5	Database updated
6	Resources available
7	Report now avaılable
8	New rwd recommendations
9	New tool available

No	Text
1	Projects (2)
2	Programs of related projects (2)
3	Upcoming events
4	Recommendations
5	Tools
6	Publications
7	New cttı project aims to ıncrease ınclusion of minority pop****tions in clinical trials
8	Cttı paper discusses development of patient group engagement tool to benefit clinical trials
9	Cttı paper discusses suitability of patient registries for embedded clinical trials
10	Cttı feasibility studies database adds new resources
11	Recording now available: strategies for engaging racial and ethnic minority patient pop****tions in covıd-19 trials
12	Web conference recordings available: listen to stakeholder engagement on ıch e6 guideline for good clinical practice
13	Share your experiences: recognizing the need for diversity in covıd-19 clinical trials

No	Text
1	Antibiotic drug development
2	Digital health trials
3	Article (7)
4	Program: antibacterial drug development
5	Program: digital health trials

Text Styling

STRONG4
B0
EM1
I0
U0
CITE3

STRONG

No	Text
1	CTTI Policy Impact
2	Adoption of CTTI's QbD Framework
3	Adoption of Central IRB's
4	Disclaimer:

No	Text
1	Copyright © CTTI 2020. All Rights Reserved

CITE

No	Text
1	CTTI Policy Impact
2	Adoption of CTTI's QbD Framework
3	Adoption of Central IRB's

LINK ANALYSIS

Total Link Count: 149

Internal Link Count : 140

No	Text	Type
1	n a v	text
2	Who We Are	text
3	What We Do	text
4	Briefing Room	text
5	Take Action	text
6	Contact Us	text
7	Login	text
8	-	empty
9	Who We Are	text
10	Strategic Plan	text
11	Organizational Structure	text
12	Executive Committee	text
13	Staff	text
14	Steering Committee	text
15	Members***p	text
16	Annual Members***p Fees	text
17	Become A Member	text
18	Become a Patient/Caregiver Rep	text
19	Benefits & Responsibilities	text
20	Funding	text
21	Annual Reports	text
22	What We Do	text
23	Recommendations	text
24	Implementation Tools	text
25	Projects	text
26	COVID-19	text
27	Data Monitoring Committees (DMCs)	text
28	Electronic Healthcare Data	text
29	Increasing Diversity in Clinical Trials	text
30	Informed Consent	text
31	Informing the Update of ICH E6	text
32	Investigator Community	text
33	Investigator Qualification	text
34	Large Simple Trials	text
35	Long-Term Opioid Data	text
36	Master Protocol Studies	text
37	Patient Engagement Collaborative (PEC)	text
38	Patient Groups & Clinical Trials	text
39	Pregnancy Testing	text
40	Quality by Design	text
41	Real-World Data	text
42	Recruitment	text
43	Registry Trials	text
44	Safety Reporting	text
45	Single IRB	text
46	Site Metrics	text
47	State of Clinical Trials	text
48	Programs of Related Projects	text
49	Antibiotic Drug Development	text
50	HABP/VABP Studies	text

External Link Count : 9

No	Text	Type
1	Join Our Newsletter	text
2	NIH draft Policy	text
3	FDA’s newest draft guidance on IND safety reporting	text
4	FDA's Guidance on Risk-Based Monitoring	text
5	EMA Reflection Paper	text
6	21st Century Cures	text
7	-	empty
8	-	empty
9	Web Design by NMC	text